Space News from SpaceDaily.com
Press Release from Business Wire: Variational AI, Inc.
(AFP) Sep 23, 2025
VANCOUVER, Sept 23, 2025 (BSW) - Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI's Enki? platform to design and optimize novel small molecule candidates against two undisclosed targets.

Under the agreement, Variational AI will use a fine-tuned version of its Enki? platform trained on Merck's proprietary data to generate and optimize small molecule candidates against therapeutic targets designated by Merck. Merck will have the exclusive right to develop and commercialize compounds arising from the collaboration. Variational AI will receive an upfront payment and is eligible to receive milestones with a total potential deal value of up to USD$349 million.

"We are excited to apply our proprietary machine learning algorithms to Merck's extensive and valuable datasets to create unique, fine-tuned generative models of unprecedented power and accuracy," said Handol Kim, CEO of Variational AI. "This is a compelling framework that has the potential to significantly accelerate and redefine the unit economics of drug discovery."

"At Merck, we are working to harness the potential of AI to improve efficiency, speed, and quality of candidates earlier in the discovery continuum," said Robert M. Garbaccio, Ph.D., Vice President and Head of Discovery Chemistry, Merck Research Laboratories. "We look forward to working with Variational AI to apply their Enki? platform to challenging therapeutic targets."

Variational AI's Enki? platform is based on a foundation model trained on Variational AI's internal data, curated version of the totality of all publicly-available data, and proprietary generative models to create and optimize small molecules leads based on partner target product profiles.

About Variational AI

Variational AI is a venture-backed generative AI drug discovery company based in Vancouver, Canada. Founded by machine learning researchers from MIT, Caltech, Google Research, Microsoft Research, and D-Wave Quantum, its proprietary Enki? platform uses state-of-the-art generative AI models to design novel, optimized small molecules with improved probability of success, thereby accelerating the discovery and development of transformative therapeutics. For more information, please visit www.variational.ai.



View source version on businesswire.com: https://www.businesswire.com/news/home/20250923751722/en/




Contact

Media Contacts:Variational AIHandol Kim, [email protected] 604-761-7199

Valentin Beuchillot, Marketing [email protected] 236-818-8624



© 2025 Business Wire, Inc.Disclaimer:This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.


ADVERTISEMENT




Space News from SpaceDaily.com
Maven stays silent after routine pass behind Mars
ICE-CSIC leads a pioneering study on the feasibility of asteroid mining
NASA JPL Unveils Rover Operations Center for Moon, Mars Missions

24/7 Energy News Coverage
Thorium plated steel points to smaller nuclear clocks
Solar ghost particles seen flipping carbon atoms in underground detector
Overview Energy debuts airborne power beaming milestone for space based solar power

Military Space News, Nuclear Weapons, Missile Defense
Autonomous DARPA project to expand satellite surveillance network by BAE Systems
IAEA calls for repair work on Chernobyl sarcophagus
Momentus joins US Space Force SHIELD contract vehicle

24/7 News Coverage
UAlbany Atmospheric Scientist Proposes Innovative Method to Reduce Aviation's Climate Impact
Digital twin successfully launched and deployed into space
Robots that spare warehouse workers the heavy lifting


All rights reserved. Copyright Agence France-Presse. Sections of the information displayed on this page (dispatches, photographs, logos) are protected by intellectual property rights owned by Agence France-Presse. As a consequence, you may not copy, reproduce, modify, transmit, publish, display or in any way commercially exploit any of the content of this section without the prior written consent of Agence France-Presse.